Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells is Mediated by Oxidative Stress

Chemotherapeutic regimens for the treatment of colorectal cancer generally include oxaliplatin, although inherent and acquired resistance is common. One potential mediator of oxaliplatin sensitivity is the non-receptor protein tyrosine kinase, Src, the activity of which correlates with disease stage...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kopetz, Scott, Lesslie, Donald P., Dallas, Nikolas A., Park, Serk I., Johnson, Marjorie, Parikh, Nila U., Kim, Michael P., Abbruzzese, James L., Ellis, Lee M., Chandra, Joya, Gallick, Gary E.
Format: Artigo
Langue:Inglês
Publié: 2009
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2709758/
https://ncbi.nlm.nih.gov/pubmed/19383922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-2246
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires